growth%20hormone%20deficiency
GROWTH HORMONE DEFICIENCY
Growth hormone deficiency in adults reflects an absence of two hormones, growth hormone and insulin-like growth factor-1 (IGF-1), affecting the process of glucose-insulin metabolism, lipolysis and bone remodelling.
History may show pituitary adenoma, surgery &/or radiation treatment of pituitary adenomas or cranial radiation for other disorders, deficiency of other pituitary hormones that may occur concurrently with growth hormone deficiency, and previous childhood growth hormone deficiency.
Physical exam reveals reduced lean body mass with increased weight, body fat predominantly in the abdominal region, thin & dry skin, cool peripheries, poor venous access and blunt affect.

Follow Up

Adults

  • Monitor monthly initially for response to treatment & adjust dose accordingly
  • Plasma glucose should be checked initially & every 3 months
  • Once maintenance doses are achieved, measurement of serum fasting blood sugar (FBS), insulin-like growth factor 1 (IGF-1), hemoglobin A1c (HbA1c), waist circumference, body mass index (BMI), serum free T4, & clinical assessment of hypothalamic-pituitary-adrenal axis or by early morning cortisol or cosyntropin stimulation test (in patients not on glucocorticoid replacement), testosterone, & fasting lipid panel should be done every 6-12 months
  • DEXA (Dual Energy X-ray Absorptiometry) scan is recommended prior to & during growth hormone (GH) therapy
    • 1st DEXA scan after initiation of GH replacement should be done at approx 2 years later & repeated at 2-3 year intervals

Children

  • Monitor every 3-6 months for response to treatment & adjust dose accordingly
  • Monitor thyroid function every 6 months
  • Continue GH therapy if there is persistent growth hormone deficiency (GHD) even after adult height is achieved to obtain full skeletal/muscle maturation during the transition period
  • GHD may persist to adult life
    • Retesting may be required esp in idiopathic GHD patients (retest using adult criteria after 1-3 months w/o GH therapy)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Roshini Claire Anthony, 4 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

07 Jun 2019
Low-dose aspirin therapy does not confer significant benefits to elderly patients with hypertension, but treatment appears to increase the risk of haemorrhagic events, suggest a Japan study.
4 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.